Screener
Sutro Biopharma STRO Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Sutro Biopharma’s 10-Q, filed August 12, 2026. Open the filing →
- Filed
- Aug 12, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-345748
FAQ
- What is Sutro Biopharma's net income?
- Sutro Biopharma (STRO) reported net income of -$38.53M in Q2 2026.
- How has Sutro Biopharma's net income changed year-over-year?
- Sutro Biopharma's net income decreased by 235.1% year-over-year, from -$11.5M to -$38.53M.
- What is the long-term trend for Sutro Biopharma's net income?
- Over 3 years (2021 to 2025), Sutro Biopharma's net income has grown at a 21.9% compound annual growth rate (CAGR), from -$105.54M to -$191.09M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Sutro Biopharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude